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1.  Introduction 
Huntington’s disease (HD) is a devastating autosomal dominant neurodegenerative condition 
caused by a CAG repeat expansion in the gene encoding huntingtin which is characterized by 
progressive motor impairment, cognitive decline and neuropsychiatric disturbances. There are 
currently no disease-modifying treatments available to patients, but a number of  therapeutic 
strategies are currently being investigated, chief among them nucleotide-based ‘gene silencing’ 
approaches, modulation of huntingtin post-translation modification and enhancing clearance of 
the mutant protein [1].  
In  2008  our  previous  review  highlighted  the  need  to  develop  and  validate  biomarkers  and 
provide a systematic head-to-head comparison of such measures. We searched the PubMed 
database  for  publications  since  2008  which  covered  each  of  the  subheadings  below.  We 
identified from these lists studies which had relevance to biomarker development, as defined in 
our previous review. Building on a tradition of collaborative research in HD, great advances 
have been made in the field since that time and we are now in a position to recommend a range 
of outcome measures with potential to assess efficacy in future therapeutic trials.   
 
2.  Biomarkers for Clinical Trials 
2.1 Neuroimaging 
It has long been established that neuroimaging can demonstrate changes within the brain in 
both early HD subjects and premanifest gene carriers, with both regional and global measures 
sensitive to change from the very early stages. There is now increasing recognition of the role of 
white matter in the degenerative process, with widespread change detectable more than 15 
years before expected disease onset [2;3]. Thanks to large-scale studies such as TRACK-HD 
[2] and PREDICT-HD [3], we now have evidence that these imaging metrics are able to show 
reproducible  group  differences  across  multiple  sites  and  that  change  over  time  can  be 
demonstrated robustly in this slowly progressive disease over periods as short as 12 months, a 
timeframe which is realistic for clinical trials [4]. The greatest effect sizes have been reported 
using rates of caudate loss, with global measures also demonstrating great power to detect 
disease-related change, providing sample sizes which could feasibly be recruited for therapeutic 
trials  [5].  TRACK-HD  has  also  demonstrated  the  primacy  of  cross-site  standardization  and 
robust quality control measures to ensure consistency of this data.  
More recently, imaging modalities other than structural MRI have been proposed as suitable 
candidates for clinical trials. Diffusion weighted imaging (DWI), which specifically investigates 
the structural integrity of white matter, has demonstrated change over time in early HD subjects 
[6], although this finding was not reproduced by a larger study [7]. Functional MRI (fMRI) has 
the  potential  to  detect  disease-related  variation  in  brain  activity,  showing  cross-sectional 
differences prior to disease onset [8]. However, a recent study failed to show change over a two 
year  period  [9].  Whilst  fMRI  and  DWI  remain  highly  promising  candidates  for  probing 
dysfunctions in neural networks that are the hallmark of premanifest HD, further work is required 
to  investigate  their  sensitivity  to  longitudinal  change  as  well  as  validate  measures  across 
multiple sites before the clinical utility of these modalities are established.   
 
Other  recent  work  has  shown  cross-sectional  disease-related  differences  in  motor  cortex 
excitability using transcranial magnetic stimulation [10]. Altered metabolite profiles, suggested of 
neuronal dysfunction have also been reported in early HD and treatments aiming to improve 
neuronal health might effectively be assessed using such a metric [11]. Again, further cross-site 
validation and follow-up data is required to assess the utility of these modalities.  
 
 
 
2.2 Quantitative clinical measures 
Clinical ratings scales remain the most widely used measures of progression in Huntington’s 
disease. However, due to their large inter-rater variability and floor and ceiling effects, recent 
work has focused on more objective techniques which may better capture the range of deficits 
in both early and premanifest stages of disease.  
Quantitative motor assessments such as finger tapping, grip force and tongue protrusion tasks, 
have  shown  significant  cross-sectional  effects  across  the  disease  spectrum  [2].  These 
measures have also demonstrated robust change over time in early HD subjects [4;12]; effect 
sizes  suggest  such  metrics  may  prove  useful  as  outcome  measures  in  clinical  trials  [5]. 
However, they are relatively insensitive in the  premanifest stage showing  small effect sizes 
longitudinally [12]. Similarly oculomotor and neuropsychiatric assessments which show cross-
sectional disease-related deficits [2], appear to be relatively insensitive to longitudinal change 
over periods of time which would be feasible for clinical trials [5].  
Numerous  studies  have  shown  cross-sectional  cognitive  deficits,  even  many  years  before 
disease onset [2;3]. Longitudinal studies have shown change over time in early HD, although 
effect  sizes  vary  considerably  depending  on  the  specific  cognitive  test  employed  [5;13]. 
Sensitivity to change in the premanifest stages is again very limited [5].  
 
2.3  Biofluids 
Robust, pathologically relevant changes in accessible biofluids such as blood  remain highly 
desirable. The pathways previously highlighted as suggesting potential biomarkers remain of 
interest, particularly oxidative,  metabolic and inflammatory markers. These require testing in 
samples derived from multiple populations and over time, to establish their potential utility for 
future  clinical  trials.  Newly  identified  biomarker  candidates  that  require  further  investigation 
include cholesterol metabolites [14] and indirect markers of transcriptional dysregulation such as 
the histone component H2AFY [15]. Meanwhile clusterin, which our own work revealed as a 
possible HD plasma biomarker [16], has since been highlighted as a major genetic modifier and 
possible blood biomarker of Alzheimer’s disease [17]. 
   
Accurately measuring levels of  mutant (mHtt) and wild-type huntingtin in biosamples will be 
essential  for  testing  therapeutics  aimed  at  reducing  mHtt  levels  –  including  promising 
nucleotide-based ‘gene silencing’ treatments expected to enter clinical trials in the near future, 
as well as drugs aimed at altering the handling and removal of mHtt through post-translational 
modification and proteolysis. Existing Htt assays have suffered from low sensitivity and been 
restricted  to  aggregated  mHtt.  A  recently  described  agarose  gel  electrophoresis  assay 
(‘AGERA’) has lowered the threshold for aggregate detection and quantification [18], but the role 
of aggregates is debated and it is likely that soluble oligomeric mHtt is most toxic. Until recently, 
the detection of soluble Htt was limited by the intrinsic insensitivity of assays, and a lack of 
suitable antibodies. Novel antibodies and a fluorescence-enhanced antibody assay using time-
resolved  Förster  resonence  energy  transfer  (TR-FRET)  has  now  yielded  a  reliable,  highly 
sensitive method of quantifying both mutant and total huntingtin in blood samples [19]. This 
assay is likely to empower future clinical trials. Meanwhile, attempts are underway to develop 
assays that are even more sensitive and scalable.  
 
 
Given  its  close  biochemical  and  physical  relationship  with  the  brain,  and  utility  in  other 
neurodegenerative diseases as a source of biomarkers, cerebrospinal fluid (CSF) has natural 
appeal, despite being time-consuming and more invasive than phlebotomy. Efforts to identify 
CSF biomarkers for HD have been hampered by a shortage of samples and lack of consistency 
between  existing  small  collections.  In  one  major  study,  proteomic  data  generated from  one 
sample set by five laboratories were integrated, revealing changes (mainly reductions) in many 
brain-specific  proteins,  but  raising  concerns  about  consistency  between  laboratories  [20]. 
Pursuing a hypothesis-driven approach, another group has identified neurofilament light chain 
and tau as potential neuron-specific CSF markers [21]; but neither provides complete separation 
from controls or has been studied longitudinally. Multi-site longitudinal CSF collection studies 
are in the planning stage. 
 
3.  Future directions 
3.1 Neuroimaging 
It  is  clear  from  studies  such  as  TRACK-HD  and  PREDICT-HD  that  there  are  striking 
neuropathological  changes  up  to  15  years  prior  to  the  onset  of  manifest  disease  [2,3]. 
Nevertheless,  these  subjects  maintain  their  performance  on  functional  measures.  It  would 
appear that there is a compensatory mechanism within the brain which finally breaks down at 
disease onset [8]; imaging modalities other than structural MRI will be required to elucidate this 
process. TrackOn-HD seeks to apply novel imaging techniques across multiple sites, following 
the premanifest cohort from the TRACK-HD study. Whether these imaging modalities are able 
to produce metrics which are robust and sensitive enough to be used in clinical trials is yet to be 
determined.  
A means of quantifying wild-type and mutant huntingtin in the brain would be a valuable tool for 
demonstrating CNS target engagement of huntington-lowering therapies in the main organ of 
interest, especially since early gene silencing therapeutics are likely to be delivered directly into 
the CNS rather than systemically. Work is underway to develop and test PET ligands that will 
enable visualisation of huntington load, as a predictive tool and a means of assessing response 
to therapy. 
 
3.2 Quantitative clinical measures 
Further refinement and validation is required if objective quantitative measures of motor and 
cognitive  function  are  to  demonstrate  sensitivity  to  premanifest  disease,  or  be  accepted  as 
outcome measures in clinical trials. A number of cognitive tasks show promise as biomarkers, 
particularly  measures  of  visuospatial  integration  [4].  A  cognitive  ‘toolkit’  for  premanifest  and 
manifest  HD,  which  will  build  on  the  existing  evidence,  is  nearing  completion  [22]. 
Neuropsychiatric measures are likely to be included in future clinical trials since assessments of 
patient well-being are of paramount importance, but these too require the development of more 
reproducible and sensitive methodology. In addition to these initiatives,  ongoing longitudinal 
studies such as PREDICT-HD and TrackOn-HD seek to optimize measures in these different 
functional modalities.  
 
3.3 Biofluids 
Novel assays to measure soluble mutant huntingtin, and their refinement for high-throughput 
use, is likely to emerge as one of the most important developments in the field and will become 
a standard measure for clinical trials. The use of CSF as the biofluid of choice for interrogating 
the  CNS  milieu  is  likely  to  occur  in  HD  as  it  has  in  other  neurodegenerative  diseases,  but 
standardised, multisite, longitudinal CSF natural history studies are needed. Finally, the most 
promising biomarker candidates need to be studied ‘head-to-head’ using the large longitudinal 
blood sample collections that studies such as TRACK-HD have generated.   
 
Though a decade of research has not yielded robust biochemical biomarkers of HD, progress 
has been made. A consensus is emerging that the detection of neuron-specific proteins in blood 
may be an unrealistic aim, but since the mutant huntingtin protein is expressed ubiquitously, that 
does  not  mean  that  tracking  change  in  peripheral  tissues  lacks  merit.  What  is  needed  is 
scrupulous  study  of  how  any  measure  is  involved  in  HD  pathogenesis,  and  judicious 
interpretation of changes seen in the context of therapeutic trials. 
 
Expert Opinion 
Considerable progress has been made towards identifying biomarkers which show promise as 
outcome measures in clinical trials. Multi-national studies such as PREDICT-HD and TRACK-
HD have proved invaluable in validating measures which are robust and reproducible across 
different sites and cultures. The most recent publication from the TRACK-HD study provides a 
direct comparison of the effect sizes for a range of modalities, and outlines a battery suitable for 
use in clinical trials in early HD [5]; this includes structural neuroimaging, quantitative motor, 
cognitive and neuropsychiatric assessments. However, as yet such a battery does not exist for 
a premanifest cohort as current functional measures appear to be relatively insensitive at this 
disease stage. Neuroimaging demonstrates the largest effect sizes, but further investigation of 
the relationship between such metrics and functional performance is required. There is clearly a 
need for robust functional assessments to be included in any trial and there are now a number 
of  candidate  biomarkers  from  different  modalities  which  can  feasibly  be  implemented.  The 
individual elements of this battery selected for a particular trial will of course depend on the 
proposed  mode  of  action  of  therapy,  timeframe  and  cohort.  We  previously  predicted  that 
ultimate evaluation of biomarker candidates would need to take place within the framework of 
clinical trials of disease-modifying treatments. This model for biomarker development is now 
deployed in HD clinical trials (e.g. mHtt and interleukins are being measured as part of the 
PADDINGTON study of sirtuin-1 inhibition) and, though challenging, this approach is essential, 
since it is only when disease, biomarker and drug are studied together that the true interplay 
between them can emerge.  
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